Payment overview · 2025
General Payments
$9,508.73
111 reported records · 15 companies
Healthcare provider profile · identity verified
Hong Chen
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BROOKLYN, NY · NPI 1689921934
Verified facts
What the public records show
CMS Open Payments records show Hong Chen received $9,508.73 in general payments during 2025 across 111 reported records.
Phathom Pharmaceuticals, Inc. accounted for 46.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Creon, Jardiance, Licart, Mounjaro, Nexletol, Otezla, Qulipta, Rybelsus, Shingrix, Ubrelvy, Voquezna, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Licart as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Licart by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Rybelsus by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Voquezna by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,406.70 | 46.3% | 14 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $2,730.45 | 28.7% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $549.44 | 5.8% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $421.55 | 4.4% | 9 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $275.92 | 2.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $268.16 | 2.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $194.12 | 2.0% | 8 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $187.10 | 2.0% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.55 | 1.7% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $110.72 | 1.2% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $79.71 | 0.8% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $67.21 | 0.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.55 | 0.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.25 | 0.2% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $16.30 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,010.00 | 5 |
| Food and Beverage | $3,367.82 | 101 |
| Travel and Lodging | $1,130.91 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4,406.70 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $401.97 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $381.97 | 11 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $275.92 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $268.16 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $187.10 | 11 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $147.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $120.39 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.51 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.93 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $79.71 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $67.21 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.96 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.22 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $22.47 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 40 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 34 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| Licart licart |
2025 | Licart | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 70 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 109 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 99 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
96 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
87 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
50 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
161 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
124 | 30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
173 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
40 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
99 | 55 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Licart open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Licart · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
109 | 20 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Epolamine | Diclofenac Epolamine | 1019 | 180 |
| Vascepa | Icosapent Ethyl | 819 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 752 | 143 |
| Losartan Potassium | Losartan Potassium | 636 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 612 | 128 |
| Metformin Hcl | Metformin Hcl | 381 | 84 |
| Mometasone Furoate | Mometasone Furoate | 346 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 343 | 75 |
| Bepotastine Besilate | Bepotastine Besilate | 339 | 93 |
| Dexlansoprazole Dr | Dexlansoprazole | 293 | 67 |
| Donepezil Hcl | Donepezil Hcl | 290 | 59 |
| Meclizine Hcl | Meclizine Hcl | 280 | 91 |
| Raloxifene Hcl | Raloxifene Hcl | 239 | 58 |
| Diclofenac Potassium | Diclofenac Potassium | 225 | 56 |
| Alendronate Sodium | Alendronate Sodium | 223 | 42 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 223 | 72 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 197 | 44 |
| Trazodone Hcl | Trazodone Hcl | 185 | 63 |
| Omeprazole | Omeprazole | 183 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 37 |
| Vemlidy | Tenofovir Alafenamide | 173 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 170 | 53 |
| Gabapentin | Gabapentin | 166 | 45 |
| Januvia | Sitagliptin Phosphate | 163 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 36 |
| Farxiga | Dapagliflozin Propanediol | 161 | 40 |
| Ammonium Lactate | Ammonium Lactate | 152 | 58 |
| Alcohol Pads | Alcohol Antiseptic Pads | 151 | 55 |
| Promethazine Hcl | Promethazine Hcl | 150 | 100 |
| Meloxicam | Meloxicam | 145 | 55 |
| Montelukast Sodium | Montelukast Sodium | 144 | 45 |
| Simvastatin | Simvastatin | 142 | 29 |
| Clobetasol Propionate | Clobetasol Propionate | 134 | 49 |
| Nexium | Esomeprazole Magnesium | 124 | 30 |
| Finasteride | Finasteride | 120 | 25 |
| Restasis | Cyclosporine | 117 | 29 |
| Glipizide Er | Glipizide | 113 | 14 |
| Allopurinol | Allopurinol | 109 | 22 |
| Rybelsus | Semaglutide | 109 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 20 |
| Atenolol | Atenolol | 102 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 99 | 55 |
| Halobetasol Propionate | Halobetasol Propionate | 96 | 41 |
| Linzess | Linaclotide | 96 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 94 | 31 |
| Dutasteride | Dutasteride | 94 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 50 |
| Azithromycin | Azithromycin | 92 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 22 |
| Kerendia | Finerenone | 88 | 18 |
| Synthroid | Levothyroxine Sodium | 87 | 11 |
| Ursodiol | Ursodiol | 84 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 17 |
| Jardiance | Empagliflozin | 73 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 34 |
| Ketoconazole | Ketoconazole | 70 | 17 |
| Nexletol | Bempedoic Acid | 70 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 64 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 60 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 20 |
| Ibuprofen | Ibuprofen | 59 | 44 |
| Azelastine Hcl | Azelastine Hcl | 58 | 15 |
| Zenpep | Lipase/Protease/Amylase | 57 | 17 |
| Metformin Er Gastric | Metformin Hcl | 56 | suppressed |
| Xarelto | Rivaroxaban | 55 | 17 |
| Celecoxib | Celecoxib | 53 | 14 |
| Metformin Hcl Er | Metformin Hcl | 53 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 18 |
| Trulance | Plecanatide | 53 | suppressed |
| Lisinopril | Lisinopril | 52 | suppressed |
| Ezetimibe | Ezetimibe | 51 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 37 |
| Prolia | Denosumab | 50 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 27 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 49 | 25 |
| Amoxicillin | Amoxicillin | 47 | 31 |
| Famotidine | Famotidine | 47 | 11 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 46 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 34 |
| Procto-Med Hc | Hydrocortisone | 44 | 19 |
| Licart | Diclofenac Epolamine | 42 | 12 |
| Memantine Hcl Er | Memantine Hcl | 42 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 40 | 39 |
| Telmisartan | Telmisartan | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 30 |
| Creon | Lipase/Protease/Amylase | 34 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| True Comfort Alcohol Pads | Alcohol Antiseptic Pads | 33 | 26 |
| Baclofen | Baclofen | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | 13 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Ciclopirox | Ciclopirox | 27 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Naproxen | Naproxen | 26 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 13 |
| Mupirocin | Mupirocin Calcium | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Voquezna | Vonoprazan Fumarate | 24 | suppressed |
| Denta 5000 Plus | Fluoride (Sodium) | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 16 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Qulipta | Atogepant | 23 | suppressed |
| Sodium Fluoride 5000 Plus | Fluoride (Sodium) | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Otezla | Apremilast | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Edarbi | Azilsartan Medoxomil | 16 | suppressed |
| Furosemide | Furosemide | 16 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | 14 |
| Nystatin | Nystatin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Brilinta | Ticagrelor | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Sf 5000 Plus | Fluoride (Sodium) | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,508.73 · 111 records | Phathom Pharmaceuticals, Inc. | AIRSUPRA, AREXVY, BREZTRI, CREON, FASENRA, Flector, GEMTESA, JARDIANCE, KRYSTEXXA, Korlym, Licart, MOUNJARO, NEXLETOL, NUCALA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, Tirosint, UBRELVY, VOQUEZNA, VYALEV, XIFAXAN, ZENPEP, ZEPBOUND | 24 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error